Second pivotal Phase III trial of cobimetinib plus atezolizumab versus a PD-1 inhibitor in patients with previously untreated BRAF wild-type advanced melanoma

Trial Profile

Second pivotal Phase III trial of cobimetinib plus atezolizumab versus a PD-1 inhibitor in patients with previously untreated BRAF wild-type advanced melanoma

Planning
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms IMspire170
  • Sponsors Genentech
  • Most Recent Events

    • 20 Jul 2017 This trial is expected to begin in the third quarter of 2017, according to an Exelixis media release.
    • 01 May 2017 According to an Exelixis media release, this trial is expected to enroll its first patient in the second quarter of 2017.
    • 21 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top